Although the mechanism mediating these different effects remains uncertain, it is implied that cooccurrence of SHPT in CKD stage 3b-4 group (increased serum osteocalcin, P1NP, and TRAP5b levels) might be responsible for this difference. Here, BGLAP is linked to chronic kidney disease.